Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Cancer Drug Therapy Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Targeted Therapy
  • 1.3.3 Chemotherapy
  • 1.3.4 Immunotherapy
• 1.4 Market Segment by Application
  • 1.4.1 Global Cancer Drug Therapy Market Share by Application (2019-2025)
  • 1.4.2 Angiogenesis Inhibitors
  • 1.4.3 mTOR Inhibitors
  • 1.4.4 Monoclonal Antibodies
  • 1.4.5 Cytokine Immunotherapy (IL-2)
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Cancer Drug Therapy Market Size
  • 2.1.1 Global Cancer Drug Therapy Revenue 2014-2025
  • 2.1.2 Global Cancer Drug Therapy Sales 2014-2025
• 2.2 Cancer Drug Therapy Growth Rate by Regions
  • 2.2.1 Global Cancer Drug Therapy Sales by Regions 2014-2019
  • 2.2.2 Global Cancer Drug Therapy Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Cancer Drug Therapy Sales by Manufacturers
  • 3.1.1 Cancer Drug Therapy Sales by Manufacturers 2014-2019
  • 3.1.2 Cancer Drug Therapy Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Cancer Drug Therapy Revenue by Manufacturers (2014-2019)
  • 3.2.2 Cancer Drug Therapy Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Cancer Drug Therapy Market Concentration Ratio (CR5 and HHI)
• 3.3 Cancer Drug Therapy Price by Manufacturers
• 3.4 Key Manufacturers Cancer Drug Therapy Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Cancer Drug Therapy Market
• 3.6 Key Manufacturers Cancer Drug Therapy Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Targeted Therapy Sales and Revenue (2014-2019)
  • 4.1.2 Chemotherapy Sales and Revenue (2014-2019)
  • 4.1.3 Immunotherapy Sales and Revenue (2014-2019)
• 4.2 Global Cancer Drug Therapy Sales Market Share by Type
• 4.3 Global Cancer Drug Therapy Revenue Market Share by Type
• 4.4 Cancer Drug Therapy Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Cancer Drug Therapy Sales by Application

6 United States

• 6.1 United States Cancer Drug Therapy Breakdown Data by Company
• 6.2 United States Cancer Drug Therapy Breakdown Data by Type
• 6.3 United States Cancer Drug Therapy Breakdown Data by Application

7 European Union

• 7.1 European Union Cancer Drug Therapy Breakdown Data by Company
• 7.2 European Union Cancer Drug Therapy Breakdown Data by Type
• 7.3 European Union Cancer Drug Therapy Breakdown Data by Application

8 China

• 8.1 China Cancer Drug Therapy Breakdown Data by Company
• 8.2 China Cancer Drug Therapy Breakdown Data by Type
• 8.3 China Cancer Drug Therapy Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Cancer Drug Therapy Breakdown Data by Company
• 9.2 Rest of World Cancer Drug Therapy Breakdown Data by Type
• 9.3 Rest of World Cancer Drug Therapy Breakdown Data by Application
• 9.4 Rest of World Cancer Drug Therapy Breakdown Data by Countries
  • 9.4.1 Rest of World Cancer Drug Therapy Sales by Countries
  • 9.4.2 Rest of World Cancer Drug Therapy Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Amgen / Allergan
  • 10.1.1 Amgen / Allergan Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.1.4 Cancer Drug Therapy Product Introduction
  • 10.1.5 Amgen / Allergan Recent Development
• 10.2 Argos Therapeutics
  • 10.2.1 Argos Therapeutics Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.2.4 Cancer Drug Therapy Product Introduction
  • 10.2.5 Argos Therapeutics Recent Development
• 10.3 AstraZeneca
  • 10.3.1 AstraZeneca Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.3.4 Cancer Drug Therapy Product Introduction
  • 10.3.5 AstraZeneca Recent Development
• 10.4 Aveo Pharmaceuticals
  • 10.4.1 Aveo Pharmaceuticals Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.4.4 Cancer Drug Therapy Product Introduction
  • 10.4.5 Aveo Pharmaceuticals Recent Development
• 10.5 Bayer
  • 10.5.1 Bayer Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.5.4 Cancer Drug Therapy Product Introduction
  • 10.5.5 Bayer Recent Development
• 10.6 Exelixis
  • 10.6.1 Exelixis Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.6.4 Cancer Drug Therapy Product Introduction
  • 10.6.5 Exelixis Recent Development
• 10.7 Incyte
  • 10.7.1 Incyte Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.7.4 Cancer Drug Therapy Product Introduction
  • 10.7.5 Incyte Recent Development
• 10.8 Merck
  • 10.8.1 Merck Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.8.4 Cancer Drug Therapy Product Introduction
  • 10.8.5 Merck Recent Development
• 10.9 Roche
  • 10.9.1 Roche Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.9.4 Cancer Drug Therapy Product Introduction
  • 10.9.5 Roche Recent Development
• 10.10 Bristol-Myers Squibb
  • 10.10.1 Bristol-Myers Squibb Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Cancer Drug Therapy
  • 10.10.4 Cancer Drug Therapy Product Introduction
  • 10.10.5 Bristol-Myers Squibb Recent Development
• 10.11 Eisai
• 10.12 Exelixis
• 10.13 Genentech (Roche)
• 10.14 Novartis
• 10.15 Pfizer
• 10.16 Prometheus Labs

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Cancer Drug Therapy Sales Channels
  • 11.2.2 Cancer Drug Therapy Distributors
• 11.3 Cancer Drug Therapy Customers

12 Market Forecast

• 12.1 Global Cancer Drug Therapy Sales and Revenue Forecast 2019-2025
• 12.2 Global Cancer Drug Therapy Sales Forecast by Type
• 12.3 Global Cancer Drug Therapy Sales Forecast by Application
• 12.4 Cancer Drug Therapy Forecast by Regions
  • 12.4.1 Global Cancer Drug Therapy Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Cancer Drug Therapy Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Kidney cancer or renal cancer is one of the ten most frequently diagnosed cancers, found mainly in people aged 60 or above. According to the estimates of the American Cancer Society (ACS), 61,560 new kidney cancer cases and 14,080 deaths would occur in 2015. Due to the increasing prevalence with no cure of this deadly disease, till date, there is an imminent need for effective kidney cancer drugs.

The renal cancer drug therapy market has witnessed a dramatic change in its treatment paradigm over the last three decades. Although, there are a variety of treatment options available, innovators have now shifted their focus towards more targeted therapies and immunotherapies. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors boosting the growth of the market. Strong pipeline and fast-emerging treatments are expected to further boost the market during the analysis period. However, high cost of drugs, looming off-patents and uncertain reimbursement policies are some of the factors that are likely to restrain the market growth.

Winning a physicians confidence regarding the cost, efficacy and dosage would lead to a higher acceptance of drugs in the market. Additionally, immunotherapies would emerge as an opportunity for innovators in the kidney cancer drugs market. Furthermore, untapped geographies with a high undiagnosed patient base would offer lucrative opportunities for the innovators in future. However, overcoming the generic drugs competition would be a key challenge for the leading innovators.
In 2019, the market size of Cancer Drug Therapy is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Cancer Drug Therapy.

This report studies the global market size of Cancer Drug Therapy, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Cancer Drug Therapy sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Amgen / Allergan
Argos Therapeutics
AstraZeneca
Aveo Pharmaceuticals
Bayer
Exelixis
Incyte
Merck
Roche
Bristol-Myers Squibb
Eisai
Exelixis
Genentech (Roche)
Novartis
Pfizer
Prometheus Labs

Market Segment by Product Type
Targeted Therapy
Chemotherapy
Immunotherapy

Market Segment by Application
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Cancer Drug Therapy status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Cancer Drug Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Cancer Drug Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025